UNSPSC 51285503: Ditophal

This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40SR2754GL. European Medicines Agency schedules Ditophal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06336MIG. Ditophal generally arises in the molecular formula C12H14O2S2. The term DITOPHAL is an International Non-Proprietary Name or INN. DITOPHAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule ditophal under HS 29309085 and SITC 51549. As of Q4 2014, DITOPHAL remains the US FDA Preferred Term for this commodity. Ditophal bears US NLM identifiers UMLS ID C1880369 and NCI Concept Code C65445. SMILES: CCSC(=O)C1=CC(=CC=C1)C(=O)SCC.

UNSPSC 51285503 Ditophal is a Commodity code under which state and local governments procure pharmaceutical products and medical supplies, though the recent opportunities block shows limited activity explicitly tagged to this code. The work being solicited includes naloxone and drug deactivation systems (Seminole County), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance), medical and first aid supplies for fire departments (City of Tampa), and exploratory vendor outreach for direct-to-manufacturer pharmacy benefit programs (Texas Health and Human Services Commission). Issuing bodies span county health departments, state pharmacy commissions, cities with emergency services, and multi-state cooperative purchasing alliances. The recent opportunities reflect a mix of direct procurement for tactical public health needs and strategic market-testing for statewide or multi-state pharmaceutical supply chains.

Recent activity appears concentrated in Florida, Minnesota, Texas, and the Tampa Bay region. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; response due July 26, 2023) for 1,900 naloxone units and 800 drug deactivation systems with quarterly deliveries; the City of Tampa's IFB 26-P-00145 (posted March 25, 2026; response due March 13, 2026) for medical and first aid supplies to the Fire Department Rescue Division, designated as a sheltered market for certified Small Local Business Enterprises with a $700,000 estimated contract value and a 5 percent SLBE bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026; response due March 26, 2026) seeking generic pharmaceuticals and OTC products from manufacturers, with awards effective July 1, 2026, through authorized wholesalers. The Texas HHS RFI issued April 3, 2026, represents preliminary market research rather than formal procurement. Award cycles run one to two years with renewal options, and most solicitations require firm pricing, delivery timeframes of five to ten working days, and compliance with FDA and cGMP standards.